Table 2 Cancer associated pathway analysis.
Pathway | T vs. N | T vs. NB | T vs. ND | NB vs. ND |
|---|---|---|---|---|
Role of BRCA1 in DNA Damage Response | 6.99E-07↑ | 4.75E-01 | 3.05E-09↑ | 2.09E-06↑ |
C2M DNA Damage Checkpoint Regulation | 1.03E-03↑ | 3.53E-01 | 7.46E-04↑ | 8.07E-06↑ |
p53 Signaling | 1.50E-02 | 5.85E-02 | 1.77E-04↑ | 5.11E-06↑ |
G1/S Checkpoint Regulation | 2.94E-02 | - | 4.22E-02 | 1.47E-03↑ |
PPAR signaling | 6.41E-02 | 1.33E-01 | 1.78E-02 | 1.03E-03↓ |
EGF Signaling | - | 1.49E-02 | 3.94E-01 | 1.49E-01 |
p38 MARK Signaling | 1.77E-01 | 1.69E-01 | 1.74E-01 | 1.01E-01 |
PDGF Signaling | 2.11E-01 | 7.20E-03↑ | 8.31E-02 | 7.56E-02 |
NF-kB Signaling | 2.13E-01 | 6.61E-02 | 3.03E-01 | 3.35E-02 |
ERK/MAPK Signaling | - | 3.22E-01 | 6.64E-02 | 5.20E-01 |
VEGF Signaling | - | - | 3.15E-01 | 1.71E-01 |
IGF-1 Signaling | - | - | 3.83E-01 | 1.28E-01 |
TGF-β Signaling | - | - | 5.00E-01 | 5.09E-01 |
cAMP-mediated Signaling | - | - | - | 4.21E-01 |
FGF Signaling | - | 4.70E-01 | - | 3.62E-01 |